Sphingosine type 1 inhibitors and methods for making and using same
US2010035959A1
Sphingosine kinase type 1 inhibitors, compositions and processes for using same
IL179366D0
Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
US2010298308A1
Compositions and methods for bone formation and remodeling
US2007037284A1
Vectors for expressing exogenous gene or exogenous nucleic acid sequences
US2006183228A1
Viral vectors with surface or envelope components
EP2409732A1
Compositions and methods for bone formation and remodeling
US2006079442A1
Methods and uses of leptin in hepatocellular carcinoma
CN101123986A
Glucocerebroside treatment of disease
CA2540672A1
Educated nkt cells and their uses in the treatment of immune-related disorders
WO2005032462A2
Glucocerebroside treatment of disease
US2004171527A1
Regulation of immune responses by manipulation of intermediary metabolite levels
EP1569686A2
Transmucosal administration of aggregated antigens
US2003170258A1
Novel processes implementing selective immune down regulation (SIDR)
US8012456B2
Biological models capable of exhibiting secondary disease manifestations and useful for developing therapeutic drugs, diagnostic products and therapeutic or diagnostic procedures, methods of using same, and cells, tissues and organs derived therefrom
IL142802D0
Use of one or more hbv antigens for the preparation of oral pharmaceutical compositions for treating a subject having an active hbv infection or hepatocellular carcinoma
JP2001172187A
New selective immune down regulation (sidr) mediated transplantation process, process for preventing or treating disease in test specimen and composition comprising trained or programmed cell, tissue or organ, useful for establishing sidr
CA2313739A1
Model animals of human retrovirus infection
IL131979D0
Vectors and viral vectors and packaging cell lines for propagating the same
CA2596292A1
Vectors and viral vectors, and packaging cell lines for propagating same
